{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:00:29Z","timestamp":1775840429075,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enterohemorrhagic HUS (eHUS), triggered by Shiga toxin (STX), is a thrombotic microangiopathy and major cause of acute kidney injury (AKI) in children. Of those hospitalized, ~65% require dialysis, while others may suffer seizures, neurocognitive deficits from cerebral ischemia, other organ failure (\u2009~\u200930%), and death (3-5%). Long-term sequelae include chronic kidney disease, hypertension, insulin-dependent diabetes, and neurocognitive impairment. No therapeutic agents are effective and\/or approved by the Food and Drug Administration, or similar bodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We have identified two potential therapeutic targets\u2014mannose-binding lectin-2 (MBL2) of the lectin complement pathway and clotting factor XIa (FXIa) of the intrinsic coagulation pathway. We previously reported the importance of MBL2 in a mouse model of Shiga Toxin-induced kidney injury, using 3F8, a mouse anti-human MBL2 antibody, and procoagulant activity in an endothelial monolayer model. We now report important roles for both clotting factor XI and MBL2 in this model, employing 3G3, a humanized anti-FXIa antibody, and 3F8 together.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The antibody combination is superior to either antibody alone in reducing glomerular platelet deposition, and to 3F8 in reducing fibrin deposition. Only the combination is effective in lowering AKI, hemolysis, and weight loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The antibody combination may have therapeutic application in affected children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Enterohemorrhagic hemolytic uremic syndrome causes acute renal failure in 65% of affected children, seizures and neurocognitive deficits from cerebral ischemic events in 3\u20135%, other organ system failure in 20\u201330%, and death in 3\u20135%. There presently exists no specific therapy, only supportive care.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>We have found in our mouse model of Shiga Toxin-induced kidney injury that monoclonal antibodies against the mannose binding lectin-2 (MBL2) of the lectin complement pathway, and factor XI\/XIa of the contact coagulation pathway show clear benefit used singly, but even greater benefit in combination.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The combination offers promise for an effective first specific therapy.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-025-04535-7","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:36:13Z","timestamp":1775831773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibodies to mannose-binding\u00a0lectin and factor XI Inhibit Shiga toxin-induced kidney injury additively in a murine model"],"prefix":"10.1038","author":[{"given":"Eric F.","family":"Grabowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory L.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celestina","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivy","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel O.","family":"Skjoedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Redwan","family":"Binrouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie R.","family":"Ingelfinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"4535_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2217\/fmb.10.4","volume":"5","author":"VL Tesh","year":"2010","unstructured":"Tesh, V. L. Induction of apoptosis by Shiga toxins. Future Microbiol 5, 431\u201353 (2010).","journal-title":"Future Microbiol"},{"key":"4535_CR2","first-page":"126","volume":"21","author":"FT Koster","year":"1984","unstructured":"Koster, F. T., Boonpucknavig, V., Sujaho, S., Gilman, R. H. & Rahaman, M. M. Renal histopathology in the hemolytic-uremic syndrome following shigellosis. Clin. Nephrol. 21, 126\u2013133 (1984).","journal-title":"Clin. Nephrol."},{"key":"4535_CR3","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.kint.2016.05.011","volume":"90","author":"M Ozaki","year":"2016","unstructured":"Ozaki, M. et al. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. Kidney Int 90, 774\u2013782 (2016).","journal-title":"Kidney Int"},{"key":"4535_CR4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1538-7836.2005.01205.x","volume":"4","author":"E Nestoridi","year":"2005","unstructured":"Nestoridi, E. et al. Shiga toxin enhances functional tissue factor on activated human glomerular endothelial cells. J. Thromb. Haemost. 4, 752\u2013762 (2005).","journal-title":"J. Thromb. Haemost."},{"key":"4535_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.thromres.2013.03.006","volume":"131","author":"EF Grabowski","year":"2013","unstructured":"Grabowski, E. F., Kushak, R. I., Liu, B. & Ingelfinger, J. R. Shiga toxin downregulates tissue factor pathway inhibitor, modulating an increase in the expression of functional tissue factor on endothelium. Thromb. Res. 131, 521\u2013528 (2013).","journal-title":"Thromb. Res."},{"key":"4535_CR6","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.thromres.2015.03.018","volume":"135","author":"EF Grabowski","year":"2015","unstructured":"Grabowski, E. F., Liu, B., Gerace, M. R., Kushak, R. I. & Ingelfinger, J. R. Shiga toxin-1 decreases endothelial cell tissue factor pathway inhibitor not co-localized with tissue factor on the cell membrane. Thromb. Res. 135, 1214\u20131217 (2015).","journal-title":"Thromb. Res."},{"key":"4535_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","volume":"39","author":"CU Lorentz","year":"2019","unstructured":"Lorentz, C. U. et al. The contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial. Arterioscler. Thromb. Vasc. Biol. 39, 799\u2013809 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"4535_CR8","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021011725","volume":"138","author":"CU Lorentz","year":"2021","unstructured":"Lorentz, C. U. et al. Contact activation inhibitor, AB023, in heparin-free hemodialysis: Results of a randomized phase 2 clinical trial. Blood 138, 2173\u20132184 (2021).","journal-title":"Blood"},{"key":"4535_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/MBC.0000000000000720","volume":"29","author":"EM Conway","year":"2018","unstructured":"Conway, E. M. Complement-coagulation connections. Blood Coagul. Fibrinolysis 29, 243\u2013251 (2018).","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"4535_CR10","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1084\/jem.185.9.1619","volume":"185","author":"F Tedesco","year":"1997","unstructured":"Tedesco, F. et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J. Exp. Med. 185, 1619\u20131627 (1997).","journal-title":"J. Exp. Med."},{"key":"4535_CR11","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","volume":"185","author":"U Amara","year":"2010","unstructured":"Amara, U. et al. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 185, 5628\u20135636 (2010).","journal-title":"J. Immunol."},{"key":"4535_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4049\/jimmunol.1100491","volume":"187","author":"M Morigi","year":"2011","unstructured":"Morigi, M. et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J. Immunol. 187, 172\u2013180 (2011).","journal-title":"J. Immunol."},{"key":"4535_CR13","doi-asserted-by":"publisher","first-page":"885","DOI":"10.4049\/jimmunol.1102916","volume":"188","author":"LR La Bonte","year":"2012","unstructured":"La Bonte, L. R. et al. Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J. Immunol. 188, 885\u2013891 (2012).","journal-title":"J. Immunol."},{"key":"4535_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.imbio.2010.02.005","volume":"216","author":"K Takahashi","year":"2011","unstructured":"Takahashi, K. et al. Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology 216, 96\u2013102 (2011).","journal-title":"Immunobiology"},{"key":"4535_CR15","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1371\/journal.pone.0000623","volume":"2","author":"A Krarup","year":"2007","unstructured":"Krarup, A., Wallis, R., Presenis, J. S., Gal, P. & Sim, R. B. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One 2, e623 (2007).","journal-title":"PLoS One"},{"key":"4535_CR16","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.4049\/jimmunol.2000398","volume":"206","author":"C Puy","year":"2021","unstructured":"Puy, C. et al. Crosstalk between the complement pathway and the contact activation system of coagulation: activated factor XI neutralizes complement factor H. J. Immunol. 206, 1784\u20131792 (2021).","journal-title":"J. Immunol."},{"key":"4535_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ajpath.2014.10.015","volume":"185","author":"VI Pavlov","year":"2015","unstructured":"Pavlov, V. I. et al. Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model. Am. J. Pathol. 185, 347\u2013355 (2015).","journal-title":"Am. J. Pathol."},{"key":"4535_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00251-013-0689-6","volume":"65","author":"RM Kj\u00e6rup","year":"2013","unstructured":"Kj\u00e6rup, R. M., Norup, L. R., Skj\u00f8dt, K., Dalgaard, T. S. & Juul-Madsen, H. R. Chicken mannose-binding lectin (MBL) gene variants with influence on MBL serum concentrations. Immunogenetics 65, 461\u2013471 (2013).","journal-title":"Immunogenetics"},{"key":"4535_CR19","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1182\/blood-2011-10-386185","volume":"119","author":"EI Tucker","year":"2012","unstructured":"Tucker, E. I. et al. Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood 119, 4762\u20134768 (2012).","journal-title":"Blood"},{"key":"4535_CR20","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1111\/jth.15777","volume":"20","author":"KR Jordan","year":"2021","unstructured":"Jordan, K. R. et al. Pharmacological reduction of coagulation factor XI reduces macrophage accumulation and accelerates deep venous thrombosis resolution in a mouse model of venous thrombosis. J. Thromb. Haemost. 20, 2035\u20132045 (2021).","journal-title":"J. Thromb. Haemost."},{"key":"4535_CR21","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0002-9440(10)65026-2","volume":"156","author":"CD Collard","year":"2000","unstructured":"Collard, C. D. et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am. J. Pathol. 156, 1549\u20131556 (2000).","journal-title":"Am. J. Pathol."},{"key":"4535_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1365-2125.2009.03491.x","volume":"68","author":"EA Dubois","year":"2009","unstructured":"Dubois, E. A. & Cohen, A. F. Eculizumab. Br. J. Clin. Pharmacol. 68, 318\u2013319 (2009).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"4535_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0161-5890(83)90090-1","volume":"20","author":"BL Pacella","year":"1983","unstructured":"Pacella, B. L., Hui, K. Y., Haber, E. & Matsueda, G. R. Induction of fibrin-specific antibodies by immunization with synthetic peptides that correspond to amino termini of thrombin cleavage sites. Mol. Immunol. 20, 521\u2013527, https:\/\/doi.org\/10.1016\/0161-5890(83)90090-1 (1983).","journal-title":"Mol. Immunol."},{"key":"4535_CR24","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1016\/S0021-9258(18)32568-7","volume":"258","author":"RP McEver","year":"1983","unstructured":"McEver, R. P., Bennett, E. M. & Martin, M. N. Identification of two structurally and functionally distinct sites on human platelet membrane glycoprotein IIb-IIIa using monoclonal antibodies. J. Biol. Chem. 258, 5269\u20135275 (1983).","journal-title":"J. Biol. Chem."},{"key":"4535_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1055\/s-0040-1709525","volume":"120","author":"EF Grabowski","year":"2020","unstructured":"Grabowski, E. F., Van Cott, E. M., Bornikova, L., Boyle, D. C. & Silva, R. L. Differentiation of Patients with Symptomatic Low von Willebrand Factor from Those with Asymptomatic Low von Willebrand Factor. Thromb. Haemost. 120, 793\u2013804 (2020).","journal-title":"Thromb. Haemost."},{"key":"4535_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.thromres.2011.12.016","volume":"129","author":"EF Grabowski","year":"2012","unstructured":"Grabowski, E. F., Curran, M. A. & Van Cott, E. M. Assessment of a Cohort of Primarily Pediatric Patients with a Presumptive Diagnosis of Type 1 Von Willebrand Disease with a Novel High Shear Rate, Non-Citrated Blood Flow Device. Thromb. Res. 129, 18\u201324 (2012).","journal-title":"Thromb. Res."},{"key":"4535_CR27","doi-asserted-by":"publisher","first-page":"F865","DOI":"10.1152\/ajprenal.00078.2019","volume":"317","author":"EJ Baldelomar","year":"2019","unstructured":"Baldelomar, E. J., Charlton, J. R., deRonde, K. A. & Bennett, K. M. In vivo measurements of kidney glomerular number and size in healthy and Os\/+ mice using MRI. Am. J. Physiol. Ren. Physiol. 317, F865\u2013F873 (2019).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"4535_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.30802\/AALAS-CM-23-000033","volume":"73","author":"MA Suckow","year":"2023","unstructured":"Suckow, M. A. & Tirado-Mu\u00f1iz, N. Seasonal variation of laboratory animals a consideration for research reproducibility. Comp. Med. 73, 255\u2013259 (2023).","journal-title":"Comp. Med."},{"key":"4535_CR29","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1111\/j.1523-1755.2005.00329.x","volume":"67","author":"E Nestoridi","year":"2005","unstructured":"Nestoridi, E., Tsukurov, O., Kushak, R. I., Ingelfinger, J. R. & Grabowski, E. F. Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int 67, 2254\u20132266 (2005).","journal-title":"Kidney Int"},{"key":"4535_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000228159","volume":"2","author":"DP Eisen","year":"2010","unstructured":"Eisen, D. P. Mannose-binding lectin deficiency and respiratory tract infection. J. Innate Immun. 2, 114\u201322 (2010).","journal-title":"J. Innate Immun."},{"key":"4535_CR31","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1056\/NEJMoa1106482","volume":"365","author":"U Buchholz","year":"2011","unstructured":"Buchholz, U. et al. German Outbreak of Escherichia coli O104:H4 Associated with Sprouts. N. Engl. J. Med. 365, 1763\u20131770 (2011).","journal-title":"N. Engl. J. Med."},{"key":"4535_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1538-7933.2004.00638.x","volume":"2","author":"SA Ghosh","year":"2004","unstructured":"Ghosh, S. A., Polanowski-Grabowska, R. K., Fujii, J., Obrig, T. & Gear, A. R. L. Shiga toxin binds to activated platelets. J. Thromb. Haemost. 2, 499\u2013506 (2004).","journal-title":"J. Thromb. Haemost."},{"key":"4535_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4565","volume":"345","author":"J Menne","year":"2012","unstructured":"Menne, J. et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case control study. BMJ 345, e4565 (2012).","journal-title":"BMJ"},{"key":"4535_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.transci.2016.04.010","volume":"54","author":"LS Keir","year":"2016","unstructured":"Keir, L. S. & Langman, C. B. Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis. Transfus. Apher. Sci. 54, 203\u2013211 (2016).","journal-title":"Transfus. Apher. Sci."},{"key":"4535_CR35","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1001\/jama.290.10.1337","volume":"290","author":"H Trachtman","year":"2003","unstructured":"Trachtman, H. et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 290, 1337\u20131344 (2003).","journal-title":"JAMA"},{"key":"4535_CR36","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jama.288.8.996","volume":"288","author":"N Safdar","year":"2002","unstructured":"Safdar, N., Said, A., Gangnon, R. E. & Maki, D. G. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 288, 996\u20131001 (2002).","journal-title":"JAMA"},{"key":"4535_CR37","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJM200006293422601","volume":"342","author":"CS Wong","year":"2000","unstructured":"Wong, C. S., Jelacic, S., Habeeb, R. L., Watkins, S. L. & Tarr, P. I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342, 1930\u20131936 (2000).","journal-title":"N. Engl. J. Med."},{"key":"4535_CR38","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1681\/ASN.0000000000000182","volume":"34","author":"A Garnier","year":"2023","unstructured":"Garnier, A. et al. Efficacy and safety of eculizumab in pediatric patients affected by Shiga Toxin-related hemolytic and uremic syndrome: A randomized, placebo-controlled trial. J. Am. Soc. Nephrol. 34, 1561\u20131573, https:\/\/doi.org\/10.1681\/ASN.0000000000000182 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4535_CR39","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.2215\/CJN.02730409","volume":"4","author":"JM Thurman","year":"2009","unstructured":"Thurman, J. M. et al. Alternative Pathway of Complement in Children with Diarrhea-Associated Hemolytic uremic Syndrome. Clin. J. Am. Soc. Nephrol. 4, 1920\u20131924 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"4535_CR40","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","volume":"182","author":"D Orth","year":"2009","unstructured":"Orth, D. et al. Shiga Toxin Activated and Binds Factor H: Evidence for an Active Role of complement in Hemolytic Uremic Syndrome. J. Immunol. 182, 6394\u20136400 (2009).","journal-title":"J. Immunol."},{"key":"4535_CR41","first-page":"637","volume":"144","author":"AIA Bernabeu","year":"2020","unstructured":"Bernabeu, A. I. A., Escribano, T. C. & Vilarino, M. C. Atypical hemolytic uremic syndrome: New challenges in the complement blockage era. Nephron 144, 637\u2013649 (2020).","journal-title":"Nephron"},{"key":"4535_CR42","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/STROKEAHA.113.004111","volume":"45","author":"X de la Rosa","year":"2014","unstructured":"de la Rosa, X. et al. Mannose-binding lectin promotes local microvascular thrombosis after transient brain ischemia in mice. Stroke 45, 1453\u20131459 (2014).","journal-title":"Stroke"},{"key":"4535_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0002-9440(10)63839-4","volume":"162","author":"GL Stahl","year":"2003","unstructured":"Stahl, G. L. et al. Role for the alternative complement pathway in ischemia\/reperfusion injury. Am. J. Pathol. 162, 449\u2013455 (2003).","journal-title":"Am. J. Pathol."},{"key":"4535_CR44","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/ki.2010.393","volume":"79","author":"X Qing","year":"2011","unstructured":"Qing, X. et al. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int 79, 331\u2013339 (2011).","journal-title":"Kidney Int"},{"key":"4535_CR45","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1600-6143.2011.03887.x","volume":"12","author":"P van der Pol","year":"2012","unstructured":"van der Pol, P. et al. Mannan-binding lectin mediates renal ischemia\/reperfusion injury independent of complement activation. Am. J. Transplant. 12, 877\u2013887 (2012).","journal-title":"Am. J. Transplant."},{"key":"4535_CR46","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","volume":"122","author":"S Jodele","year":"2013","unstructured":"Jodele, S. et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 122, 2003\u20132007 (2013).","journal-title":"Blood"},{"key":"4535_CR47","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2016-11-749879","volume":"129","author":"S Subramanian","year":"2017","unstructured":"Subramanian, S. et al. Distinct Contributions of Complement Factors to Platelet Activation and Fibrin Formation in Venous Thrombus Development. Blood 129, 2291\u20132302 (2017).","journal-title":"Blood"},{"key":"4535_CR48","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A. & Bell, L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25, 1256\u20131264 (2007).","journal-title":"Nat. Biotechnol."},{"key":"4535_CR49","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/art.21157","volume":"52","author":"SS Pierangeli","year":"2005","unstructured":"Pierangeli, S. S. et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 52, 2120\u20132124 (2005).","journal-title":"Arthritis Rheum."},{"key":"4535_CR50","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00253-015-7236-3","volume":"100","author":"YS Chan","year":"2016","unstructured":"Chan, Y. S. & Ng, T. B. Shiga toxins: from structure and mechanism to applications. Appl. Microbiol. Biotechnol. 100, 1597\u20131610 (2016).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"4535_CR51","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/jcp.1041610217","volume":"161","author":"AA Khine","year":"1994","unstructured":"Khine, A. A. & Lingwood, C. A. Capping and receptor-mediated endocytosis of cell-bound Verotoxin (Shiga-Like Toxin) 1: chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization. J. Cell. Physiol. 161, 319\u2013332 (1994).","journal-title":"J. Cell. Physiol."},{"key":"4535_CR52","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1128\/iai.58.3.611-618.1990","volume":"58","author":"JE Samuel","year":"1990","unstructured":"Samuel, J. E. et al. Comparison of the glycolipid receptor specificities of Shiga-Like Toxin Type II and Shiga-Like Toxin Type II variants. Infect. Immun. 58, 611\u2013618 (1990).","journal-title":"Infect. Immun."},{"key":"4535_CR53","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.4049\/jimmunol.1102118","volume":"189","author":"C Zoja","year":"2012","unstructured":"Zoja, C. et al. Lack of the lectin-like domain of thrombomodulin worsens Shiga Toxin-associated hemolytic uremic syndrome in mice. J. Immunol. 189, 3661\u20133668 (2012).","journal-title":"J. Immunol."},{"key":"4535_CR54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1267\/ahc.13002","volume":"46","author":"S Takata","year":"2013","unstructured":"Takata, S., Sawa, Y., Uchiyama, T. & Ishikawa, H. Expression of toll-like receptor 4 in glomerular endothelial cells under diabetic conditions. Acta Histochem. Cytochem. 46, 35\u201342 (2013).","journal-title":"Acta Histochem. Cytochem."},{"key":"4535_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1574-695X.2010.00749.x","volume":"61","author":"ML Torgersen","year":"2011","unstructured":"Torgersen, M. L. et al. Toll-like receptor 4 facilitates binding of Shiga toxin to colon carcinoma and primary umbilical vein endothelial cells. FEMS Immunol. Med. Microbiol. 61, 63\u201375 (2011).","journal-title":"FEMS Immunol. Med. Microbiol."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04535-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04535-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04535-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:02:41Z","timestamp":1775836961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04535-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":55,"alternative-id":["4535"],"URL":"https:\/\/doi.org\/10.1038\/s41390-025-04535-7","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Mice in this study were treated ethically and humanely according to our institutional IACUC protocol 2018N000155.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}